These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 7975366

  • 1. [Current possibilities in the therapy of iron overload].
    Cermák J.
    Vnitr Lek; 1994 Sep; 40(9):605-8. PubMed ID: 7975366
    [Abstract] [Full Text] [Related]

  • 2. Iron chelation therapy.
    Hoffbrand AV, Wonke B.
    J Intern Med Suppl; 1997 Sep; 740():37-41. PubMed ID: 9350180
    [Abstract] [Full Text] [Related]

  • 3. [Treatment of iron overload states with oral administration of the chelator agent, L1 (Deferiprone)].
    Cermák J, Brabec V.
    Vnitr Lek; 1994 Sep; 40(9):586-90. PubMed ID: 7975362
    [Abstract] [Full Text] [Related]

  • 4. Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias.
    Kwiatkowski JL, Cohen AR.
    Hematol Oncol Clin North Am; 2004 Dec; 18(6):1355-77, ix. PubMed ID: 15511620
    [Abstract] [Full Text] [Related]

  • 5. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
    Schafer AI, Rabinowe S, Le Boff MS, Bridges K, Cheron RG, Dluhy R.
    Arch Intern Med; 1985 Jul; 145(7):1217-21. PubMed ID: 3925909
    [Abstract] [Full Text] [Related]

  • 6. Iron-chelating therapy.
    Hershko C, Weatherall DJ.
    Crit Rev Clin Lab Sci; 1988 Jul; 26(4):303-45. PubMed ID: 3077034
    [Abstract] [Full Text] [Related]

  • 7. Deferiprone: new preparation. Poorly assessed.
    Prescrire Int; 2000 Oct; 9(49):131-5. PubMed ID: 11603411
    [Abstract] [Full Text] [Related]

  • 8. Continuous high-dose intravenous desferrioxamine treatment for iron overload.
    Sidi Y, Shaklai M, Liban E, Pinkhas J.
    Isr J Med Sci; 1981 May; 17(5):348-51. PubMed ID: 7263191
    [Abstract] [Full Text] [Related]

  • 9. [Diagnosis and therapy of iron overload with desferrioxamine].
    Andres J, Stobbe H.
    Z Gesamte Inn Med; 1984 Apr 15; 39(8):167-9. PubMed ID: 6730593
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of iron-chelating agents in cultured heart muscle cells. Identification of a potential drug for chelation therapy.
    Sciortino CV, Byers BR, Cox P.
    J Lab Clin Med; 1980 Dec 15; 96(6):1081-5. PubMed ID: 7430764
    [Abstract] [Full Text] [Related]

  • 11. Hemosiderosis in a patient on regular hemodialysis: treatment by desferrioxamine.
    Baker LR, Barnett MD, Brozovic B, Cattell WR, Ackrill P, McAlister J, Nimmon C.
    Clin Nephrol; 1976 Jul 15; 6(1):326-8. PubMed ID: 954239
    [Abstract] [Full Text] [Related]

  • 12. Orally active alpha-ketohydroxypyridine iron chelators: studies in mice.
    Kontoghiorghes GJ.
    Mol Pharmacol; 1986 Dec 15; 30(6):670-3. PubMed ID: 3785144
    [Abstract] [Full Text] [Related]

  • 13. Management of iron overload in the pediatric patient.
    Cohen A.
    Hematol Oncol Clin North Am; 1987 Sep 15; 1(3):521-44. PubMed ID: 3329185
    [Abstract] [Full Text] [Related]

  • 14. [Long-term treatment of patients with transfusion hemosiderosis using oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1)].
    Goudsmit R.
    Ned Tijdschr Geneeskd; 1991 Nov 09; 135(45):2133-6. PubMed ID: 1944690
    [Abstract] [Full Text] [Related]

  • 15. New synthetic approach and iron chelating studies of 1-alkyl-2-methyl-3-hydroxypyrid-4-ones.
    Kontoghiorghes GJ, Sheppard L, Chambers S.
    Arzneimittelforschung; 1987 Oct 09; 37(10):1099-102. PubMed ID: 3435580
    [Abstract] [Full Text] [Related]

  • 16. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
    Kontoghiorghes GJ.
    Toxicol Lett; 1995 Oct 09; 80(1-3):1-18. PubMed ID: 7482575
    [Abstract] [Full Text] [Related]

  • 17. Dose response studies using desferrioxamine and orally active chelators in a mouse model.
    Kontoghiorghes GJ.
    Scand J Haematol; 1986 Jul 09; 37(1):63-70. PubMed ID: 3764334
    [Abstract] [Full Text] [Related]

  • 18. The selection and evaluation of new chelating agents for the treatment of iron overload.
    Pitt CG, Gupta G, Estes WE, Rosenkrantz H, Metterville JJ, Crumbliss AL, Palmer RA, Nordquest KW, Hardy KA, Whitcomb DR, Byers BR, Arceneaux JE, Gaines CG, Sciortino CV.
    J Pharmacol Exp Ther; 1979 Jan 09; 208(1):12-8. PubMed ID: 759605
    [Abstract] [Full Text] [Related]

  • 19. Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone.
    Nielsen P, Fischer R, Engelhardt R, Tondüry P, Gabbe EE, Janka GE.
    Br J Haematol; 1995 Dec 09; 91(4):827-33. PubMed ID: 8547125
    [Abstract] [Full Text] [Related]

  • 20. Treatment of iron overload in adults with continuous parenteral desferrioxamine.
    Cooper B, Bunn HF, Propper RD, Nathan DG, Rosenthal DS, Moloney WC.
    Am J Med; 1977 Dec 09; 63(6):958-66. PubMed ID: 605917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.